Peers of Maze Therapeutics, Inc. (MAZE)
Health Care · Pharmaceuticals
Enterprise value divided by EBITDA over the last 12 months. A common way to compare companies with different amounts of debt.
Latest EV/EBITDA
-8.84x
As of Oct 26, 2026
Beyond EV/EBITDA, the valuation view includes forward multiples, EV ratios, cash flow yields, and multi-year chart history for further research.
| Date | EV/EBITDA |
|---|---|
| Oct 26, 2026 | -8.84x |
| Oct 23, 2026 | -8.80x |
| Oct 22, 2026 | -9.17x |
| Oct 21, 2026 | -9.41x |
| Oct 20, 2026 | -9.36x |
| Oct 19, 2026 | -8.30x |
| Oct 16, 2026 | -7.46x |
| Oct 15, 2026 | -7.44x |
EV/EBITDA = Enterprise Value / EBITDA (TTM). Enterprise Value = Market Cap + Total Debt − (Cash & Short-Term Investments + Long-Term Investments).
EV/EBITDA is widely used because it removes the effects of financing and non-cash accounting items.
Read the general EV/EBITDA definition, formula, and analyst usage guide.
EV/EBITDA guideInformational research only; not personalized advice. Values reflect the latest available data on Chartloom and may differ from other sources.
